×
About 843 results

ALLMedicine™ Von Hippel-Lindau Disease Center

Research & Reviews  300 results

Systematic Review of Endolymphatic Sac Tumor Treatment and Outcomes.
https://doi.org/10.1177/01945998221108313
Otolaryngology--head and Neck Surgery : Official Journal ... Tang JD, Grady AJ et. al.

Jun 29th, 2022 - Endolymphatic sac tumors are rare neoplasms originating in the endolymphatic sac. Current literature is limited to case reports and small case series. The objective of this study was to systematically review the literature to better describe clini...

FDA Approval Summary: Belzutifan for von Hippel-Lindau disease associated tumors.
https://doi.org/10.1158/1078-0432.CCR-22-1054
Clinical Cancer Research : an Official Journal of the Ame... Fallah J, Brave MH et. al.

Jun 22nd, 2022 - On August 13, 2021, the United States Food and Drug Administration (FDA) approved belzutifan (WELIREG, Merck), a first-in-class hypoxia-inducible factor (HIF) inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy fo...

Propranolol and Von Hippel-Lindau Disease
https://clinicaltrials.gov/ct2/show/NCT05424016

Jun 21st, 2022 - 'Von Hippel-Lindau disease (VHL) is a familial syndrome, autosomal dominant, of predisposition to cancer, associating malignant tumors (renal carcinomas, neuroendocrine tumors of the pancreas), or benign tumors (retinal hemangioblastomas (HB), cer...

von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance.
https://doi.org/10.1016/j.ejmg.2022.104538
European Journal of Medical Genetics; Louise M Binderup M, Smerdel M et. al.

Jun 17th, 2022 - von Hippel Lindau disease (vHL) is caused by a hereditary predisposition to multiple neoplasms, especially hemangioblastomas in the retina and CNS, renal cell carcinomas (RCC), pheochromocytomas, neuroendocrine pancreatic tumours (PNET) and endoly...

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
https://clinicaltrials.gov/ct2/show/NCT04895748

Jun 16th, 2022 - This is a first in human (FIH), Phase I/Ib, open-label, multi-center study of DFF332 as a single agent and in combination with Everolimus or Spartalizumab plus Taminadenant in patients with advanced clear cell renal cell carcinoma and other malign...

see more →

Clinicaltrials.gov  13 results

Propranolol and Von Hippel-Lindau Disease
https://clinicaltrials.gov/ct2/show/NCT05424016

Jun 21st, 2022 - 'Von Hippel-Lindau disease (VHL) is a familial syndrome, autosomal dominant, of predisposition to cancer, associating malignant tumors (renal carcinomas, neuroendocrine tumors of the pancreas), or benign tumors (retinal hemangioblastomas (HB), cer...

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
https://clinicaltrials.gov/ct2/show/NCT04895748

Jun 16th, 2022 - This is a first in human (FIH), Phase I/Ib, open-label, multi-center study of DFF332 as a single agent and in combination with Everolimus or Spartalizumab plus Taminadenant in patients with advanced clear cell renal cell carcinoma and other malign...

A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
https://clinicaltrials.gov/ct2/show/NCT02859441

Nov 1st, 2021 - Objective: Von Hippel-Lindau (VHL) disease is an autosomal dominant heritable disorder in which multiple benign and malignant neoplasms and cysts of specific histopathologies develop in the kidney, adrenal gland, pancreas, brain, spinal cord, eye,...

PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT03108066

Apr 13th, 2021 - This open-label Phase 2 study will evaluate the efficacy, safety, PK, and PD of PT2385 in patients with VHL disease who have at least 1 measurable VHL disease-associated ccRCC tumor (as defined by RECIST 1.1). PT2385 will be administered orally an...

Von Hippel-Lindau Disease Genetic Epidemiology Study
https://clinicaltrials.gov/ct2/show/NCT00001803

Jan 13th, 2020 - The Von Hippel-Lindau (VHL) Disease Genetic Epidemiology Study is a family-based case-control study to be conducted by the National Cancer Institute. The study subjects are 603 individuals who were determined to belong to families with VHL disease...

see more →

News  19 results

2021 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

Novel Agent May Be Game-Changer in Rare Genetic Disease
https://www.medscape.com/viewarticle/963946

Dec 1st, 2021 - A novel oral agent may represent a game-changer for patients with von Hippel-Lindau (VHL) disease, a rare genetic disorder that increases the risk of renal cell carcinoma and other cancers, a new phase 2 trial suggests. The majority of patients wi...

Dr. Soares on Advances in the Management of Pancreatic NETs
https://www.onclive.com/view/dr-soares-on-advances-in-the-management-of-pancreatic-nets

Oct 20th, 2021 - Heloisa P. Soares, MD, PhD, medical oncologist, assistant professor, Huntsman Cancer Institute, University of Utah, discusses advances in the management of pancreatic neuroendocrine tumors (NETs). In January 2018, the FDA approved Lutetium 177 ...

The Nature of Neuroendocrine Tumors
https://www.onclive.com/view/the-nature-of-neuroendocrine-tumors

Sep 14th, 2021 - Matthew H. Kulke, MD: Neuroendocrine tumors are actually a very broad category of malignancies. We tend to classify them broadly in 2 big groups. One group would be pancreatic neuroendocrine tumors and the other group would be extra-pancreatic neu...

FDA OKs Belzutifan for Cancers Tied to von Hippel-Lindau Disease
https://www.medscape.com/viewarticle/956582

Aug 13th, 2021 - The US Food and Drug Administration (FDA) approved belzutifan (Welireg) for adult patients with von Hippel-Lindau disease (VHL) who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancr...

see more →

Patient Education  5 results see all →